Fahad A Bashiri1,2, Turki H Albatti3,4,5, Muddathir H Hamad1, Haya F Al-Joudi6, Hadeel F Daghash7, Saleh M Al-Salehi8, Jeremy L Varnham9, Fatimah Alhaidar3, Omar Almodayfer10, Abdulkarim Alhossein11, Hesham Aldhalaan12, Yasser A Ad-Dab'bagh13,14, Nouf Al Backer15, Waleed Altwaijri10, Khalid Alburikan16, Maysaa W Buraik17, Mohammad Ghaziuddin18, Michael J Nester19, Hayfaa A Wahabi20, Samia Alhabib21, Amr A Jamal20,21,22,23, Yasser S Amer24,25,26,27. 1. Pediatrics Department, Pediatric Neurology Division, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia. 2. Saudi Pediatric Neurology Society, Riyadh, Saudi Arabia. 3. Psychiatry Department, Child Psychiatry Unit and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia. 4. Saudi ADHD Society, Riyadh, Saudi Arabia. 5. Ministry of Education, Abdullatif Alfozan Autism Center, Al Khobar, Saudi Arabia. 6. Department of Neurosciences, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 7. Ada'a Program, Assistant Deputyship for Hospital Services, Ministry of Health, Riyadh, Saudi Arabia. 8. King Abdullah Bin Abdulaziz University Hospital, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. 9. Saudi ADHD Society, Riyadh, Saudi Arabia. jeremy@adhd.org.sa. 10. King Abdulaziz Medical City, Riyadh, Saudi Arabia. 11. Department of Special Education, King Saud University, Riyadh, Saudi Arabia. 12. Department of Neurosciences, Center for Autism Research, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 13. Department of Mental Health, Neuroscience Center, King Faisal Specialist Hospital-Dammam (KFSH-D), Dammam, Saudi Arabia. 14. Research Center, King Khalid Medical City (RC-KKMC), Dammam, Saudi Arabia. 15. Department of Pediatrics, Developmental-Behavioral Pediatrics Division, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia. 16. Saudi Pharmaceutical Society, Riyadh, Saudi Arabia. 17. Neuroscience Institute, Psychiatry Division, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia. 18. Department of Psychiatry, University of Michigan, Ann Arbor, USA. 19. Child and Adolescent Services, Ann Arbor, USA. 20. Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University, Riyadh, Saudi Arabia. 21. National Centre for Evidence-Based Health Practice, Saudi Health Council, Riyadh, Saudi Arabia. 22. Family and Community Medicine Department, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia. 23. National Centre for Health Information, Saudi Health Council, Riyadh, Saudi Arabia. 24. Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University, Riyadh, Saudi Arabia. yamer@ksu.edu.sa. 25. CPG Unit, Quality Management Department, King Saud University Medical City, Riyadh, Saudi Arabia. yamer@ksu.edu.sa. 26. Pediatrics Department, King Saud University Medical City, Riyadh, Saudi Arabia. yamer@ksu.edu.sa. 27. Alexandria Center for Evidence-Based Clinical Practice Guidelines, Alexandria University, Alexandria, Egypt. yamer@ksu.edu.sa.
Abstract
BACKGROUND: We recently adapted the published National Institute for Health and Care Excellence (NICE) Attention deficit hyperactivity disorder (ADHD) diagnosis and management guideline to the Saudi Arabian context. It has been postulated that adaptation of evidence-based clinical practice guidelines to the local healthcare context rather than de-novo development will improve their adoption and implementation without imposing a significant burden on resources. The objective of this paper is to describe the adaptation process methodology utilized for the generation of the first national guideline for management of people with ADHD in Saudi Arabia. METHODS: We used the KSU-Modified-ADAPTE methodology for the guideline adaptation process. We describe the full process in detail including the three phases of set-up, adaptation, and finalization. The process was conducted by a multidisciplinary guideline adaptation group in addition to an external review for the clinical content and methodology. RESULTS: The group adapted ten main categories of recommendations from one source CPG (NICE). The recommendations include: (i) service organisation and training, (ii) recognition, identification and referral, (iii) diagnosis, (iv) support, (v) managing ADHD, (vi) dietary advice, (vii) medication, (viii) maintenance and monitoring, (ix) adherence to treatment, and (x) review of medication and discontinuation. Several implementation tools were compiled and developed to enhance implementability including a clinical algorithm, quality measures, coding system, medication tables, translations, patient information, and online resources. CONCLUSIONS: The finalized clinical practice guideline provides healthcare providers with applicable evidence-based guidance for the management of people with ADHD in Saudi Arabia. The project also demonstrated the effectiveness of KSU-Modified-ADAPTE, and emphasized the value of a collaborative clinical and methodological expert group for adaptation of national guidelines.
BACKGROUND: We recently adapted the published National Institute for Health and Care Excellence (NICE) Attention deficit hyperactivity disorder (ADHD) diagnosis and management guideline to the Saudi Arabian context. It has been postulated that adaptation of evidence-based clinical practice guidelines to the local healthcare context rather than de-novo development will improve their adoption and implementation without imposing a significant burden on resources. The objective of this paper is to describe the adaptation process methodology utilized for the generation of the first national guideline for management of people with ADHD in Saudi Arabia. METHODS: We used the KSU-Modified-ADAPTE methodology for the guideline adaptation process. We describe the full process in detail including the three phases of set-up, adaptation, and finalization. The process was conducted by a multidisciplinary guideline adaptation group in addition to an external review for the clinical content and methodology. RESULTS: The group adapted ten main categories of recommendations from one source CPG (NICE). The recommendations include: (i) service organisation and training, (ii) recognition, identification and referral, (iii) diagnosis, (iv) support, (v) managing ADHD, (vi) dietary advice, (vii) medication, (viii) maintenance and monitoring, (ix) adherence to treatment, and (x) review of medication and discontinuation. Several implementation tools were compiled and developed to enhance implementability including a clinical algorithm, quality measures, coding system, medication tables, translations, patient information, and online resources. CONCLUSIONS: The finalized clinical practice guideline provides healthcare providers with applicable evidence-based guidance for the management of people with ADHD in Saudi Arabia. The project also demonstrated the effectiveness of KSU-Modified-ADAPTE, and emphasized the value of a collaborative clinical and methodological expert group for adaptation of national guidelines.
Entities:
Keywords:
ADHD; Adaptation; Attention deficit hyperactivity disorder; Eastern mediterranean region; Evidence-based medicine; Mental health; Practice guideline; Saudi Arabia
Authors: Ayedh A Al-Ahmari; Rishi K Bharti; Mohammad S Al-Shahrani; Muffarah H Alharthi; Hassan M Alqarni; Hassan M Alshehri Journal: J Family Community Med Date: 2018 Sep-Dec